A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
作者： Peter N. Morcos , Linda Chang , Rohit Kulkarni , Mylene Giraudon , Nancy Shulman
DOI: 10.1007/S00228-013-1556-Y
关键词:
摘要: Purpose The aim of this study was to evaluate the effects danoprevir in combination with low-dose ritonavir (danoprevir/r) and placebo plus on pharmacokinetics probe drugs for cytochrome P450 (CYP) 3A CYP2C9, patients chronic hepatitis C.
springer.com
sci-hub.se 参考文章(27)
Barbara J. Brennan, Zhi-Xin Xu, Joseph F. Grippo, Effect of peginterferon alfa‐2a (40KD) on cytochrome P450 isoenzyme activity British Journal of Clinical Pharmacology. ,vol. 75, pp. 497- 506 ,(2013) , 10.1111/J.1365-2125.2012.04373.X
Sandrine Turpault, William Brian, Robert Van Horn, Alix Santoni, Franck Poitiers, Yves Donazzolo, Xavier Boulenc, Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A British Journal of Clinical Pharmacology. ,vol. 68, pp. 928- 935 ,(2009) , 10.1111/J.1365-2125.2009.03548.X
Samir K. Gupta, Karen Kolz, David L. Cutler, Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C European Journal of Clinical Pharmacology. ,vol. 67, pp. 591- 599 ,(2011) , 10.1007/S00228-010-0972-5
Patrick Marcellin, Stuart K Roberts, K Rajender Reddy, Stephen A Harrison, Donald M Jensen, Stephanos Hadziyannis, Moises Diago, Martin Weltman, Diethelm Messinger, Fernando Tatsch, Mario Rizzetto, Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety. ,vol. 11, pp. 901- 909 ,(2012) , 10.1517/14740338.2012.721927
Rosa F. Yeh, Vincent E. Gaver, Kristine B. Patterson, Naser L. Rezk, Faustina Baxter-Meheux, Michael J. Blake, Joseph J. Eron, Cheri E. Klein, John C. Rublein, Angela D.M. Kashuba, Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers Journal of Acquired Immune Deficiency Syndromes. ,vol. 42, pp. 52- 60 ,(2006) , 10.1097/01.QAI.0000219774.20174.64
Edward J. Gane, Regine Rouzier, Catherine Stedman, Alicja Wiercinska-Drapalo, Andrzej Horban, Linda Chang, Ying Zhang, Pratibha Sampeur, Isabel Nájera, Patrick Smith, Nancy S. Shulman, Jonathan Q. Tran, Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. Journal of Hepatology. ,vol. 55, pp. 972- 979 ,(2011) , 10.1016/J.JHEP.2011.01.046
Ravi Rajagopalan, Shawn Misialek, Sarah K. Stevens, David G. Myszka, Barbara J. Brandhuber, Joshua A. Ballard, Steven W. Andrews, Scott D. Seiwert, Karl Kossen, Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry. ,vol. 48, pp. 2559- 2568 ,(2009) , 10.1021/BI900038P
Micaela B. Reddy, Yuan Chen, Joshua Ö. Haznedar, Jennifer Fretland, Steven Blotner, Patrick Smith, Jonathan Q. Tran, Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clinical Pharmacokinectics. ,vol. 51, pp. 457- 465 ,(2012) , 10.2165/11599700-000000000-00000
Jochen Kuhlmann, Wolfgang M??ck, Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development Drug Safety. ,vol. 24, pp. 715- 725 ,(2001) , 10.2165/00002018-200124100-00001
Neill James Liptrott, Andrew Owen, None, The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? Expert Opinion on Drug Metabolism & Toxicology. ,vol. 7, pp. 341- 352 ,(2011) , 10.1517/17425255.2011.553600